Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Tumor Cells Resistant to a Microtubule-Depolymerizing Hemiasterlin Analogue, HTI-286, Have Mutations in α- or β-Tubulin and Increased Microtubule Stability

View Author Information
Cancer Therapeutics Branch, The NCI Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, Molecular and Cell Biology Department, Howard Hughes Medical Institute, University of California, Berkeley, California 94720, Oncology Research, Wyeth Research, Pearl River, New York 10965, and National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland 20892
Cite this: Biochemistry 2004, 43, 44, 13944–13954
Publication Date (Web):October 15, 2004
Copyright © 2004 American Chemical Society

    Article Views





    Other access options


    Abstract Image

    Hemiasterlins are sponge-derived tripeptides that inhibit cell growth by depolymerizing existing microtubules and inhibiting microtubule assembly. Since hemiasterlins are poor substrates for P-glycoprotein, they are attractive candidates for cancer therapy and have been undergoing clinical trials. The basis of resistance to a synthetic analogue of hemiasterlin, HTI-286 (HTI), was examined in cell populations derived from ovarian carcinoma (A2780/1A9) cells selected in HTI-286. 1A9-HTI-resistant cells (1A9-HTIR series) were 57−89-fold resistant to HTI. Cross-resistance (3−186-fold) was observed to other tubulin depolymerizing drugs, with collateral sensitivity (2−14-fold) to tubulin polymerizing agents. Evaluation of the percentage of polymerized and soluble tubulin in 1A9 parental and 1A9-HTIR cells corroborated the HTI cytotoxicity data. At 22 °C or 37 °C, in the absence of any drug, the percentage of polymerized microtubules for each of the 1A9-HTIR populations was greater than that in the 1A9 parental cells, consistent with more stable microtubules. Furthermore, microtubules in the 1A9-HTIR populations were also more resistant to depolymerization at 4 °C and had more acetylated and detyrosinated (Glu-tubulin) α-tubulin, all characteristic of more stable microtubules. The 1A9-HTIR cell populations exhibited either a single nucleotide change in the M40 β-tubulin isotype, S172A, or in two cell populations where no β-tubulin mutation was detected, mutations in the Kα-1 α-tubulin isotype, S165P and R221H in one resistant cell population and I384V in another. Unlike reports of mutations resulting in reduced drug affinity, the experimental data and location of mutations are consistent with resistance to HTI-286 mediated by microtubule-stabilizing mutations in β- or α-tubulin.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.


     Corresponding author. Telephone:  (301) 496-6611. Fax:  (301) 402-1608. E-mail:  [email protected].

     National Cancer Institute.


     Present address:  University of Ulasan, Asan Medical Center, Department of Obstetrics & Gynecology, Seoul, Korea.

     University of California.

     Wyeth Research.


     National Institutes of Health.

    Cited By

    This article is cited by 46 publications.

    1. Enrique L. Larghi, Andrea B. J. Bracca, Sebastián O. Simonetti, Teodoro S. Kaufman. Recent developments in the total synthesis of natural products using the Ugi multicomponent reactions as the key strategy. Organic & Biomolecular Chemistry 2024, 22 (3) , 429-465.
    2. Thomas J. Attard, Julie P. I. Welburn, Joseph A. Marsh, . Understanding molecular mechanisms and predicting phenotypic effects of pathogenic tubulin mutations. PLOS Computational Biology 2022, 18 (10) , e1010611.
    3. Satyajit Mahapatra, Sitanshu Sekhar Sahu. Integrating Resonant Recognition Model and Stockwell Transform for Localization of Hotspots in Tubulin. IEEE Transactions on NanoBioscience 2021, 20 (3) , 345-353.
    4. Qi-Ting Zhang, Ze-Dong Liu, Ze Wang, Tao Wang, Nan Wang, Ning Wang, Bin Zhang, Yu-Fen Zhao. Recent Advances in Small Peptides of Marine Origin in Cancer Therapy. Marine Drugs 2021, 19 (2) , 115.
    5. Suganthapriya Elayapillai, Satishkumar Ramraj, Doris Mangiaracina Benbrook, Magdalena Bieniasz, Lin Wang, Gopal Pathuri, Zitha Redempta Isingizwe, Amy L. Kennedy, Yan D. Zhao, Stanley Lightfoot, Lauri A. Hunsucker, Camille C. Gunderson. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecologic Oncology 2021, 160 (1) , 302-311.
    6. Ajeeth Adhikari, Ben Shen, Christoph Rader. Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates. Antibody Therapeutics 2021, 4 (1) , 1-15.
    7. Thomas Efferth, Mohamed E.M. Saeed, Onat Kadioglu, Ean-Jeong Seo, Samira Shirooie, Armelle T. Mbaveng, Seyed Mohammad Nabavi, Victor Kuete. Collateral sensitivity of natural products in drug-resistant cancer cells. Biotechnology Advances 2020, 38 , 107342.
    8. Anil Belur Nagaraj, Olga Kovalenko, Rita Avelar, Peronne Joseph, Annalyn Brown, Arshia Surti, Sandra Mantilla, Analisa DiFeo. Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clinical Cancer Research 2018, 24 (18) , 4588-4601.
    9. Selvaa Kumar C, Debjani Dasgupta, Nikhil Gadewal. Bioinformatics Based Understanding of Effect of Mutations in the Human β Tubulin Outside Drug Binding Sites and its Significance in Drug Resistance. The Open Bioinformatics Journal 2018, 11 (1) , 29-37.
    10. Mohadeseh Hasanpourghadi, Ashok Kumar Pandurangan, Mohd. Rais Mustafa. Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms. 2017, 15-65.
    11. Antony Joseph. Oceans. 2017, 493-554.
    12. Michelle De Witt, Alexander Gamble, Derek Hanson, Daniel Markowitz, Caitlin Powell, Saleh Al Dimassi, Mark Atlas, John Boockvar, Rosamaria Ruggieri, Marc Symons. Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. Molecular Medicine 2017, 23 (1) , 50-56.
    13. Frank Loganzo, Matthew Sung, Hans-Peter Gerber. Mechanisms of Resistance to Antibody–Drug Conjugates. Molecular Cancer Therapeutics 2016, 15 (12) , 2825-2834.
    14. Yuxi Wang, Frederick W. Benz, Yangping Wu, Qisheng Wang, Yunfeng Chen, Xiangzheng Chen, Huiyan Li, Yonghui Zhang, Rundong Zhang, Jinliang Yang. Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules. Molecular Pharmacology 2016, 89 (2) , 233-242.
    15. Donna M. Huryn, Peter Wipf. Natural Product Chemistry and Cancer Drug Discovery. 2014, 91-120.
    16. Shanghua Yin, Changqing Zeng, Malathi Hari, Fernando Cabral. Paclitaxel resistance by random mutagenesis of α-tubulin. Cytoskeleton 2013, 70 (12) , 849-862.
    17. Ilenia Pellicciotta, Chia-Ping Huang Yang, Charis A Venditti, Gary L Goldberg, Shohreh Shahabi. Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. Cancer Cell International 2013, 13 (1)
    18. Jong Cheo Lee, Ho Yong Lee, Chang Hoon Moon, Seung Ju Lee, Won Hyeok Lee, Hee Jeong Cha, Sungchan Park, Young Han Lee, Hyun Jin Park, Ho-Taek Song, Young Joo Min. Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model. Translational Oncology 2013, 6 (1) , 83-91.
    19. Shanghua Yin, Changqing Zeng, Malathi Hari, Fernando Cabral. Random Mutagenesis of β-Tubulin Defines a Set of Dispersed Mutations That Confer Paclitaxel Resistance. Pharmaceutical Research 2012, 29 (11) , 2994-3006.
    20. Venkataramana K. Sidhaye, Eric Chau, Vasudha Srivastava, Srinivas Sirimalle, Chinmayee Balabhadrapatruni, Neil R. Aggarwal, Franco R. D'Alessio, Douglas N. Robinson, Landon S. King, . A Novel Role for Aquaporin-5 in Enhancing Microtubule Organization and Stability. PLoS ONE 2012, 7 (6) , e38717.
    21. Jin Ho Baek, Chang Hoon Moon, Seung Joo Cha, Hee Soon Lee, Eui-Kyu Noh, Hawk Kim, Jong-Ho Won, Young Joo Min. Arsenic trioxide induces depolymerization of microtubules in an acute promyelocytic leukemia cell line. The Korean Journal of Hematology 2012, 47 (2) , 105.
    22. Anutosh Ganguly, Fernando Cabral. New insights into mechanisms of resistance to microtubule inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2011, 1816 (2) , 164-171.
    23. Arun Kanakkanthara, Anja Wilmes, Aurora O'Brate, Daniel Escuin, Ariane Chan, Ada Gjyrezi, Janet Crawford, Pisana Rawson, Bronwyn Kivell, Peter T. Northcote, Ernest Hamel, Paraskevi Giannakakou, John H. Miller. Peloruside- and Laulimalide-Resistant Human Ovarian Carcinoma Cells Have βI-Tubulin Mutations and Altered Expression of βII- and βIII-Tubulin Isotypes. Molecular Cancer Therapeutics 2011, 10 (8) , 1419-1429.
    24. Iryna O. Zubovych, Sarah Straud, Michael G. Roth, . Mitochondrial Dysfunction Confers Resistance to Multiple Drugs in Caenorhabditis elegans. Molecular Biology of the Cell 2010, 21 (6) , 956-969.
    25. Jiankun Qie, Wenxia Zhou, Xiunan Zhao, Junlin He, Yongxiang Zhang, Keliang Liu. Hemiasterlin Analogues with Unnatural Amino Acids at the N-Terminal and Their Inhibitory Activity on Tumor Cells. International Journal of Peptide Research and Therapeutics 2009, 15 (3) , 187-194.
    26. A. Yu. Nyporko, A. I. Yemets, V. N. Brytsun, M. O. Lozinsky, Ya. B. Blume. Structural and biological characterization of the tubulin interaction with dinitroanilines. Cytology and Genetics 2009, 43 (4) , 267-282.
    27. Tadeusz F. Molinski, Doralyn S. Dalisay, Sarah L. Lievens, Jonel P. Saludes. Drug development from marine natural products. Nature Reviews Drug Discovery 2009, 8 (1) , 69-85.
    28. Dan L. Sackett, Laurent Ozbun, Enrique Zudaire, Lisa Wessner, John M. Chirgwin, Frank Cuttitta, Alfredo Martínez. Intracellular Proadrenomedullin-Derived Peptides Decorate the Microtubules and Contribute to Cytoskeleton Function. Endocrinology 2008, 149 (6) , 2888-2898.
    29. DONNA M. HURYN, PETER WIPF. Natural product chemistry and anticancer drug discovery. 2008, 107-130.
    30. Christopher Ma, Catherine Li, Lakshmi Ganesan, Jean Oak, Susan Tsai, David Sept, Naomi S. Morrissette, . Mutations in α-Tubulin Confer Dinitroaniline Resistance at a Cost to Microtubule Function. Molecular Biology of the Cell 2007, 18 (12) , 4711-4720.
    31. Shanghua Yin, Fernando Cabral, Sudha Veeraraghavan. Amino acid substitutions at proline 220 of β-tubulin confer resistance to paclitaxel and colcemid. Molecular Cancer Therapeutics 2007, 6 (10) , 2798-2806.
    32. J. Torin Huzil, Ke Chen, Lukasz Kurgan, Jack A. Tuszynski. The Roles of β-Tubulin Mutations and Isotype Expression in Acquired Drug Resistance. Cancer Informatics 2007, 3 , 117693510700300.
    33. Marie-Anne Estève, Manon Carré, Véronique Bourgarel-Rey, Anna Kruczynski, Giuseppina Raspaglio, Cristiano Ferlini, Diane Braguer. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Molecular Cancer Therapeutics 2006, 5 (11) , 2824-2833.
    34. I. Zubovych, T. Doundoulakis, P. G. Harran, M. G. Roth. A missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance. Proceedings of the National Academy of Sciences 2006, 103 (42) , 15523-15528.
    35. Tito Fojo. Can Mutations in γ-Actin Modulate the Toxicity of Microtubule Targeting Agents?. JNCI: Journal of the National Cancer Institute 2006, 98 (19) , 1345-1347.
    36. Lan Guo, Yan Ma, Rebecca Ward, Vince Castranova, Xianglin Shi, Yong Qian. Constructing Molecular Classifiers for the Accurate Prognosis of Lung Adenocarcinoma. Clinical Cancer Research 2006, 12 (11) , 3344-3354.
    37. Antonio Tito Fojo, Michael Menefee. Microtubule Targeting Agents: Basic Mechanisms of Multidrug Resistance (MDR). Seminars in Oncology 2005, 32 , 3-8.
    38. Yesim Gökmen-Polar, Daniel Escuin, Chad D. Walls, Sharon E. Soule, Yuefang Wang, Kerry L. Sanders, Theresa M. LaVallee, Mu Wang, Brian D. Guenther, Paraskevi Giannakakou, George W. Sledge. β-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells. Cancer Research 2005, 65 (20) , 9406-9414.
    39. Chia-Ping Huang Yang, Pascal Verdier-Pinard, Fang Wang, Eva Lippaine-Horvath, Lifeng He, Dansu Li, Gerhard Höfle, Iwao Ojima, George A. Orr, Susan Band Horwitz. A highly epothilone B–resistant A549 cell line with mutations in tubulin that confer drug dependence. Molecular Cancer Therapeutics 2005, 4 (6) , 987-995.
    40. Mark S. Butler. Natural products to drugs: natural product derived compounds in clinical trials. Natural Product Reports 2005, 22 (2) , 162.
    41. Frank Loganzo, Malathi Hari, Tami Annable, Xingzhi Tan, Daniel B. Morilla, Sylvia Musto, Arie Zask, Joshua Kaplan, Albert A. Minnick, Michael K. May, Semiramis Ayral-Kaloustian, Marianne S. Poruchynsky, Tito Fojo, Lee M. Greenberger. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin. Molecular Cancer Therapeutics 2004, 3 (10) , 1319-1327.
    42. Alexey Y. Nyporko, Yaroslav B. Blume. Spatial Distribution Of Tubulin Mutations Conferring Resistance To Antimicrotubular Compounds. , 397-417.
    43. Susan Band Horwitz, Tito Fojo. Microtubule Stabilizing Agents. , 307-336.
    44. Fernando Cabral. Mechanisms of Resistance to Drugs That Interfere with Microtubule Assembly. , 337-356.
    45. Paraskevi Giannakakou, James P. Snyder. Resistance to Microtubule-Targeting Drugs. , 357-394.
    46. John J. Correia, Sharon Lobert. Molecular Mechanisms of Microtubule Acting Cancer Drugs. , 21-46.